Prescott General Partners Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Altimmune
ALT
|
+$308K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Credit Acceptance
CACC
|
+$41.2M |
| 2 |
ME
23andMe Holding Co
ME
|
+$5.45M |
| 3 |
Sana Biotechnology
SANA
|
+$1.23M |
| 4 |
Humacyte
HUMA
|
+$316K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 68.75% |
| 2 | Industrials | 13.4% |
| 3 | Consumer Discretionary | 11.43% |
| 4 | Communication Services | 5.55% |
| 5 | Healthcare | 0.87% |
Similar funds
Prescott General Partners's Q2 2022 Portfolio in Review
As of Q2 2022, Prescott General Partners held 13 positions worth $1.46B, down 34% from $2.19B the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Prescott General Partners withdrew a net $47.9M in Q2 2022, closing 1 position and reducing 3 holdings. Its most notable exit was 23andMe Holding Co, an estimated $5.45M position sold in full.
By sector, the portfolio is most concentrated in Financials at 69% of assets, up from 61% a quarter earlier, followed by Industrials and Consumer Discretionary.
Against the trend, Prescott General Partners opened a new position in Altimmune worth $585K.
- Prescott General Partners's largest Q2 2022 buy was Altimmune: 50,000 shares worth $585K.
- Prescott General Partners's biggest Q2 2022 reduction was Credit Acceptance, cutting an estimated $41.2M.
- Prescott General Partners fully exited 23andMe Holding Co in Q2 2022, selling an estimated $5.45M.
- Prescott General Partners's ten largest holdings make up 100% of its $1.46B portfolio in Q2 2022.
- Prescott General Partners opened 1 new position and closed 1 in Q2 2022.
- Prescott General Partners's portfolio value fell 34% quarter-over-quarter to $1.46B.
Based on Prescott General Partners's 13F filing for Q2 2022, filed 15 Aug 2022.